Efficacy and Safety of Dupilumab in Atopic Dermatitis
Research highlights the need for diverse data on drug efficacy in atopic dermatitis to address barriers to treatment for patients with skin of color, notes Elaine Siegfried, MD.
- Treatment resulted in "consistent decreases in disease signs and symptoms" for both White and non-White patient groups by week 152 of an open-label extension analysis of dupilumab (NCT02612454) (Dupixent; Sanofi/Regeneron).
Consistent decreases in disease signs and symptoms
Author summary: Dupilumab shows efficacy in pediatric atopic dermatitis patients.